Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immune Design (IDC) has signed a license and development agreement with MedImmune for the use and commercialisation of IDC's proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.
Subscribe to our email newsletter
GLA is a toll-like receptor 4 (TLR-4) agonist which IDC has advanced into early clinical stage development.
As per the terms of the license agreement, IDC will grant MedImmune, the worldwide biologics unit for AstraZeneca, exclusive worldwide rights to research, develop, use and commercialise the GLA adjuvant in vaccines for specific indications.
IDC will receive an upfront licensing fee and potential development, regulatory and commercial milestones totaling $212m, in addition to royalty payments on sales of marketed products.
IDC executive chairman Bruce Carter said that they were pleased to enter into this license with MedImmune.
"This relationship fits very well with IDC’s business model to advance the development of GLA and enable vaccine products that we believe will provide benefit in areas of unmet need," Carter said.